
Common Food Additive May Hinder Flu Vaccine Effectiveness
Could an additive in your food be messing with the immune process that helps you fight off the flu after receiving the influenza vaccine?
Although the seasonal influenza vaccine remains an important tool in the prevention of flu transmission, and can mitigate the virus’ harsh symptoms if it is contracted, the illness still causes
TBHQ is added to a
According to Robert Freeborn, a fourth-year graduate student who also led the study, previous studies the team conducted demonstrated that tBHQ negatively impacted CD4 T cell activation. To test their theory that tBHQ impairs the T cell response to the flu, mice were funneled into 2 groups: 1 group was fed a substance containing tBHQ, and the other was fed a substance without tBHQ. Two weeks later, both groups were given a dose of influenza. The group receiving tBHQ had notable delays in T cell activation and lower levels of viral clearance. The team also discovered, after infecting the mice with an additional (different) strain of flu virus, that the tBHQ group took twice as long—6 days versus 3–to begin recovering from this second bout of flu. “This suggests that tBHQ impaired the memory response to infection with related strains of influenza virus, which would be expected to correlate with reduced vaccination efficacy,” Freeborn wrote in a recent summary of the study’s findings that he presented at the 2019 Experimental Biology meeting.
As far as how much tBHQ is needed to tamp down immune activation, the answer is: not much. “Our study shows that a low dose of tBHQ (0.0014%) hinders the immune response to influenza infection,” Rockwell said. “This concentration is equivalent to what is found in certain human and animal foods.” In his presentation, Freeborn noted that although the allowable daily intake of tBHQ is 0.7 mg/kg/day, estimates using sample diets indicate that people could be eating as much as 7.7 mg/kg/day, or 1,100% of the recommended amount.
The exact mechanism by which tBHQ impacts T cells is not yet known. “Our in vitro studies suggest that activation of a protein called Nrf2 may play a role in how these effects occur,” Rockwell said. “But subsequent studies are needed to determine this.” No further clinical studies on the effect of tBHQ and flu are planned at the moment, although Rockwell and her team are continuing to study tBHQ’s effect on human immune cells. One of her past
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.











































































































































































































































































































